Matinas BioPharma Reports Treatment Of Patient With Limb-Threatening Mucor Infection In Its Oral MAT2203 Compassionate/Expanded Use Access Program
Portfolio Pulse from Benzinga Newsdesk
Matinas BioPharma Holdings, Inc. (NYSE:MTNB) successfully treated a patient with a severe fungal infection using its oral MAT2203 under its Compassionate/Expanded Use Access Program. The patient was discharged after six weeks of treatment.
June 24, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Matinas BioPharma Holdings, Inc. (NYSE:MTNB) successfully treated a patient with a severe fungal infection using its oral MAT2203, demonstrating the potential efficacy of its lipid nanocrystal (LNC) platform.
The successful treatment of a severe fungal infection with MAT2203 under the Compassionate/Expanded Use Access Program highlights the potential efficacy of Matinas' LNC platform. This positive outcome could boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100